"Purple Spots on the Legs" — IgA Vasculitis: From Diagnosis to Watching for Kidney Involvement

Audience
Parents whose child has been diagnosed with IgA vasculitis (Henoch-Schönlein purpura)
Target length
~1,400 words
Status
Draft v1 (translated from Japanese v1)
Original
../255_iga_vasculitis.md

Lead

A few days after a cold, purple dots spread across the child's ankles and knees. The child complained of pain and refused to walk. Most parents who encounter this have no idea at first what they are looking at.

This is a typical presentation of IgA vasculitis (formerly called Henoch-Schönlein purpura, or HSP) — a form of vasculitis specific to childhood. The majority of cases resolve on their own, but a kidney complication — IgA nephritis (purpura nephritis) — is the most important long-term concern.


What IgA Vasculitis Is

IgA vasculitis is a systemic of small blood vessels, triggered by deposition (primarily ) in vessel walls. It is the most common vasculitis in children, with peak onset between ages 2 and 11. Reported prevalence is 13–20 cases per 100,000 children per year [6].

The four cardinal features:

  1. : palpable, purpura favoring the lower limbs and buttocks. Platelet count is normal.
  2. Joint pain or arthritis: primarily affecting the knees and ankles; walking may become too painful.
  3. Abdominal pain: due to vasculitis of the gut wall; intussusception has been reported as a complication.
  4. Nephritis (purpura nephritis): manifests as and .

The 2010 EULAR/PRINTO/PRES diagnostic criteria require palpable purpura (mandatory) plus at least one of the above features [2].


Natural Course and Recurrence

The majority of IgA vasculitis episodes resolve within four to six weeks. Some children require hospitalization — for severe abdominal pain or progressive nephritis — but the mainstay of management is rest and symptomatic treatment.

Recurrence occurs in approximately 30–40% of cases. Recurrent episodes are usually milder than the first and resolve spontaneously. Even so, recording symptoms and seeking medical review during recurrence remains important.

Corticosteroids are used when severe abdominal pain or progressive nephritis is present, but are not recommended for mild disease. NSAIDs (ibuprofen and similar agents) are used to relieve joint pain, though their use requires caution in the context of renal involvement — follow physician guidance.


Purpura Nephritis — The Most Important Long-Term Complication

In IgA vasculitis, the long-term issue that matters most is kidney involvement. Reported rates of nephritis range from 30–50% [3,4], appearing as hematuria and proteinuria.

Most cases of purpura nephritis resolve without intervention, but a small proportion progress to chronic kidney disease. In long-term follow-up studies extending beyond 30 years, the proportion progressing to end-stage renal failure is approximately 2–5% [4]. Early detection and specialist involvement allow for preventive interventions in some cases.

For this reason, regular urinalysis is recommended for one to three months after diagnosis of IgA vasculitis. Monitoring whether blood or protein appears in the urine is the single most concrete action that protects long-term kidney outcomes.


Home Monitoring

The following signs are reasons to return to a clinician:

Keeping a dated record of symptom progression — the extent of purpura, severity of abdominal pain, joint mobility — is useful when the child is seen again. "More than last week, or less" is a trend that only a parent's continuous observation can capture.


Summary

The acute phase of IgA vasculitis typically resolves on its own. What matters for long-term management is surveillance for kidney involvement. Regular urinalysis in the months following diagnosis, combined with home monitoring, is the practical foundation for protecting prognosis. The visual signal — purpura on the lower limbs — tends to prompt early presentation, but it is the follow-up that defines how well this condition is managed.


References

  1. Tizard EJ, Hamilton-Ayres MJ. Henoch Schonlein purpura. Arch Dis Child Educ Pract Ed. 2008;93(1):1–8. doi:10.1136/adc.2005.083550. PMID: 18208968.
  2. Ozen S, Pistorio A, Iusan SM, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis. Ann Rheum Dis. 2010;69(5):798–806. doi:10.1136/ard.2009.116095. PMID: 20418544.
  3. Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F. Clinical outcome in children with Henoch–Schönlein nephritis. Pediatr Nephrol. 2007;22(1):64–70. doi:10.1007/s00467-006-0244-x. PMID: 17028874.
  4. Davin JC, Coppo R. Henoch-Schönlein purpura nephritis in children. Nat Rev Nephrol. 2014;10(10):563–573. doi:10.1038/nrneph.2014.126. PMID: 25113611.
  5. Japan Pediatric Society. Clinical Practice Guidelines for Henoch-Schönlein Purpura. 2013.
  6. Saulsbury FT. Henoch-Schönlein purpura. Curr Opin Rheumatol. 2001;13(1):35–40. doi:10.1097/00002281-200101000-00007. PMID: 11148714.